Wuhan Vanz Pharm Inc.

 

Wuhan Vanz Pharm Inc., Your reliable supplier!

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home News

Company News

Good quality Pharmaceutical Intermediates for sales
Good quality Pharmaceutical Intermediates for sales
I am very happy to cooperate with your company for nearly three years, thank you very attentive service, thank you for the excellent product quality.

—— Stephnie

You always have very fast delivery, very happy to cooperate with you. Thank you.

—— John

Very pleased to become your customer, and very happy for our cooperation, hope to be your long-term parter.

—— Sara

we received the package, very fast, the quality is very good, will continue to buy your products.

—— Luice

I have emailed you a couple times and they get returned as undeliverable. Yes. I am happy with the powders. thank you.

—— Bryan

I'm Online Chat Now
Company News
china latest news about Acipimox  intermediates, 5-methylpyrazine-2-carboxylic acid, cas 5521-55-1 is in the process of development

Acipimox intermediates, 5-methylpyrazine-2-carboxylic acid, cas 5521-55-1 is in the process of development

[2016-12-05 13:13:39]
Acipimox intermediates, 5-methylpyrazine-2-carboxylic acid (5521-55-1), is in the process of development, the product is expected to produce officially p in March 2017, when the design production capacity will be 30 tons per year. Read More
china latest news about a new UV absorber BP-6, cas 131-54-4 will avilable

a new UV absorber BP-6, cas 131-54-4 will avilable

[2016-12-05 13:05:17]
Our company developed a new UV absorber BP-6, cas 131-54-4. The production of products will be coming soon, and now the design of the production capacity is 2 tons per month, and we will produce it after 2 months. Welcome to consult and cooperate for all the enterprises around the world. Read More
china latest news about An intermediate product, Telmisartan intermediates, CAS : 25148-68-9 will be available

An intermediate product, Telmisartan intermediates, CAS : 25148-68-9 will be available

[2016-12-05 12:55:15]
Our company developed a new Telmisartan intermediates, N-methyl-o-phenylenediamine hydrochloride, CAS : 25148-68-9. The production of products will be coming soon in the next month, and now the design of the production capacity is 10 tons per month , The current exclusive supply is for one ... Read More
china latest news about European Commission approves BMS' ORENCIA for methotrexate-naive RA patients

European Commission approves BMS' ORENCIA for methotrexate-naive RA patients

[2016-09-09 10:57:17]
The European Commission has approved Bristol-Myers Squibb’s ORENCIA (abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, in combination with methotrexate (MTX), for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis (RA) not ... Read More
china latest news about ImmuPharma to open site in Mauritius for trial of Lupus treatment

ImmuPharma to open site in Mauritius for trial of Lupus treatment

[2016-09-09 10:55:40]
ImmuPharma has provided a further update on the progress of its Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. ImmuPharma has been requested to open a new site in Mauritius to participate in the ... Read More
china latest news about Merck’s Keytruda wins FDA breakthrough therapy status, priority review for first-line NSCLC

Merck’s Keytruda wins FDA breakthrough therapy status, priority review for first-line NSCLC

[2016-09-09 10:54:28]
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation and priority review to Merck’s Keytruda (pembrolizumab) for the first-line treatment of patients with advanced non–small cell lung cancer whose tumors express PD-L1. The agency's action date (PDUFA) is 24 December ... Read More
china latest news about Retrophin's sparsentan succeeds in phase 2 study in rare kidney disorder

Retrophin's sparsentan succeeds in phase 2 study in rare kidney disorder

[2016-09-09 10:53:07]
Retrophin said the phase 2 study of sparsentan, for the treatment of focal segmental glomerulosclerosis (FSGS), achieved statistical significance in the primary efficacy endpoint. Sparsentan was tested on 109 patients with FSGS, which is a rare kidney disorder that leads to end-stage renal disease. ... Read More
Page 1 of 1